News
AZ eyes FDA verdict on Lynparza in adjuvant breast cancer in...
The FDA will deliver a verdict on AstraZeneca’s PARP inhibitor Lynparza as an adjuvant treatment for breast cancer in the first quarter of next year, after granting the application a priori
